FibroBiologics (FBLG) Non Operating Interest Expenses (2023 - 2026)

FibroBiologics (FBLG) has reported Non Operating Interest Expenses for 4 consecutive years, with $7000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non Operating Interest Expenses changed N/A year-over-year to $7000.0; the trailing twelve-month figure through Jun 2026 stood at $215000.0 (up 1854.55% YoY), and the FY2025 full-year result was $204000.0, up 920.0% from the prior year.
• Non Operating Interest Expenses grew to $7000.0 in Q2 2026 per FBLG's latest filing, from $4000.0 in the prior quarter.
• Across five years, Non Operating Interest Expenses topped out at $204000.0 in Q4 2025 and bottomed at $1000.0 in Q4 2023.
• Historically, Non Operating Interest Expenses has averaged $38100.0 across 4 years, with a median of $5500.0 in 2024.
• The sharpest annual moves came in 2024 and 2025: Non Operating Interest Expenses slumped 97.04% in 2024, then jumped 3300.0% in 2025.
• Over 4 years, Non Operating Interest Expenses stood at $1000.0 in 2023, then surged by 500.0% to $6000.0 in 2024, then surged by 3300.0% to $204000.0 in 2025, then sank by 96.57% to $7000.0 in 2026.
• According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $7000.0, $4000.0, and $204000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.